Rocket Pharmaceuticals (NASDAQ: DMPI) and DelMar Pharmaceuticals (NASDAQ:DMPI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Insider & Institutional Ownership
85.0% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of DelMar Pharmaceuticals shares are owned by institutional investors. 47.7% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of DelMar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Rocket Pharmaceuticals and DelMar Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rocket Pharmaceuticals||N/A||N/A||-$29.49 million||N/A||N/A|
|DelMar Pharmaceuticals||N/A||N/A||-$8.08 million||($0.74)||-0.70|
This is a summary of recent recommendations and price targets for Rocket Pharmaceuticals and DelMar Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Rocket Pharmaceuticals currently has a consensus target price of $27.00, indicating a potential upside of 23.23%. DelMar Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 2,224.23%. Given DelMar Pharmaceuticals’ higher probable upside, analysts clearly believe DelMar Pharmaceuticals is more favorable than Rocket Pharmaceuticals.
This table compares Rocket Pharmaceuticals and DelMar Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Rocket Pharmaceuticals has a beta of 3.88, suggesting that its stock price is 288% more volatile than the S&P 500. Comparatively, DelMar Pharmaceuticals has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Rocket Pharmaceuticals beats DelMar Pharmaceuticals on 7 of the 9 factors compared between the two stocks.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the combined local delivery of VAL-083 and temozolomide. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.